Answers are grounded in this paper and cite their sources.
Financial toxicity is an increasingly recognized challenge in cancer care, with significant implications for patient outcomes and quality of life.Preoperative radiotherapy (PRT) offers a promising approach to mitigate this issue in the treatment of early-stage breast cancer (EBC).While hypofractionated whole-breast irradiation (HF-WBI) is the current standard of care, providing equivalent oncologic outcomes to conventional fractionation with shorter treatment duration, its implementation often requires daily treatments over several weeks, resulting in higher costs and greater patient burden, including travel, accommodation, time away from work, and caregiver demands.Short-course PRT may reduce normal tissue exposure, although assessment of delayed tumor response depends on the interval before surgery, and longterm oncologic efficacy and cosmetic outcomes require further investigation.Contemporary radiotherapy regimens include conventional fractionation (50 Gy in 25 fractions), moderate hypofractionation (40-42.5 Gy in 15-16 fractions), ultra-hypofractionation (26 Gy in 5 fractions), and accelerated partial breast irradiation (APBI), each differing in duration, cost, and resource utilization.Established postoperative regimens should be distinguished from investigational single-fraction and five-fraction PRT in selected patients.Existing literature highlights the economic advantages of shorter regimens, such as five-fraction APBI, which remain underutilized, particularly in underserved populations.PRT may address challenges in postoperative target delineation by targeting the intact tumor before surgery.However, whether PRT reduces financial toxicity remains uncertain.The preliminary, unpublished institutional savings estimate compares five-fraction PRT with 15-20-fraction postoperative treatment and has not been validated using time-driven activity-based costing (TDABC).Future prospective studies should incorporate TDABC to assess treatment delivery costs, including planning, imaging, quality assurance, and staffing, alongside clinical outcomes, cosmesis, patient-reported quality of life, time burden, and financial toxicity.
No takes yet. Share an insight, caveat, or question.
Demirors et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: